-

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company’s lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking place December 8 – 11 in Phoenix, AZ.

Details of the presentations are as follows:

Title: Functional and sexual disability, and quality of life after one dose of MM120 (lysergide) in adults with generalized anxiety disorder
Format: Poster
Presenter: Paula Jacobson, Ph.D., Executive Director, Clinical Development, MindMed

Title: Rapid and durable response to a single dose of MM120 (lysergide) in generalized anxiety disorder: A dose-optimization study
Format: Poster
Presenter: Dan Karlin, M.D., M.A., Chief Medical Officer, MindMed

Posters are available on MindMed’s Company website.

About MindMed

MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.

This press release is not sanctioned by ACNP.

Contacts

For Media: media@mindmed.co
For Investors: ir@mindmed.co
For Medical Affairs: medaffairs@mindmed.co

Industry:

Mind Medicine

NASDAQ:MNMD
Release Versions
English

Contacts

For Media: media@mindmed.co
For Investors: ir@mindmed.co
For Medical Affairs: medaffairs@mindmed.co

More News From Mind Medicine

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 18,375,000 common shares, without par value, at a public offering price of $12.25 per common share. The gross proceeds to MindMed from the offering, before deducting underwriting discounts, commissions, and other of...

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. In addition, MindMed intends to grant the underwriters an option for a period...

MindMed Announces New Employee Inducement Grant

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to one newly hired non-executive employee consisting of an option to purchase 28,000 common shares of the Company (the "Option") with an effective grant date of October 14, 2025. The Option has an exercise price equal to the closin...
Back to Newsroom